Abstract
Since the initial identification of microRNAs (miRNA) in C. elegans, functional characterisation of these small non-coding RNAs has demonstrated their critical involvement in numerous biological processes. Typically 20-22 nucleotides in length, miRNAs act as negative gene regulators at the post-transcriptional level. A large body of evidence points to the role of miRNAs in haematopoiesis. miRNAs provide a network of signals important for haematopoietic cell maintenance, lineage differentiation and cell maturation. The mechanism by which they mediate their effects in haematopoiesis is complex, demonstrating cell-specific, tissue-specific and maturation-specific expression. Understanding haematopoietic expression and key targets of miRNAs is important to further elucidate the functional roles of miRNAs. Furthermore, an appreciation of their role in normal physiological processes sheds light on the possibility that aberrations of miRNA expression may perturb these processes and cause disease. Indeed, deregulation of miRNAs has been demonstrated in oncogenesis and in haematological malignancies in particular. This review focuses on miRNA expression in normal haematopoiesis and provides brief insight into how deregulation of these miRNA may contribute to cancer pathogenesis.
Keywords: miRNA, haematopoiesis, cancer, DiGeorge Syndrome, double-stranded RNA
Current Signal Transduction Therapy
Title:MicroRNAs - Key Players in Haematopoiesis
Volume: 8 Issue: 1
Author(s): Stephanie Gounaris-Shannon, Sarah Newbury and Timothy Chevassut
Affiliation:
Keywords: miRNA, haematopoiesis, cancer, DiGeorge Syndrome, double-stranded RNA
Abstract: Since the initial identification of microRNAs (miRNA) in C. elegans, functional characterisation of these small non-coding RNAs has demonstrated their critical involvement in numerous biological processes. Typically 20-22 nucleotides in length, miRNAs act as negative gene regulators at the post-transcriptional level. A large body of evidence points to the role of miRNAs in haematopoiesis. miRNAs provide a network of signals important for haematopoietic cell maintenance, lineage differentiation and cell maturation. The mechanism by which they mediate their effects in haematopoiesis is complex, demonstrating cell-specific, tissue-specific and maturation-specific expression. Understanding haematopoietic expression and key targets of miRNAs is important to further elucidate the functional roles of miRNAs. Furthermore, an appreciation of their role in normal physiological processes sheds light on the possibility that aberrations of miRNA expression may perturb these processes and cause disease. Indeed, deregulation of miRNAs has been demonstrated in oncogenesis and in haematological malignancies in particular. This review focuses on miRNA expression in normal haematopoiesis and provides brief insight into how deregulation of these miRNA may contribute to cancer pathogenesis.
Export Options
About this article
Cite this article as:
Gounaris-Shannon Stephanie, Newbury Sarah and Chevassut Timothy, MicroRNAs - Key Players in Haematopoiesis, Current Signal Transduction Therapy 2013; 8 (1) . https://dx.doi.org/10.2174/1574362411308010012
DOI https://dx.doi.org/10.2174/1574362411308010012 |
Print ISSN 1574-3624 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-389X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Developments in Targeting Bromodomain and Extra Terminal
Domain Proteins for Cancer Therapeutics
Current Medicinal Chemistry Targeted Therapies in Solid Tumours: Pinpointing the Tumours Achilles Heel
Current Pharmaceutical Design Histamine and Histamine Receptor Antagonists in Cancer Biology
Inflammation & Allergy - Drug Targets (Discontinued) Novel Approaches for RNA Interference and their Application in Cancer Therapy
Current Pharmacogenomics Structure-Based Drug Design to Overcome Drug Resistance: Challenges and Opportunities
Current Pharmaceutical Design Anticancer α-Helical Peptides and Structure / Function Relationships Underpinning Their Interactions with Tumour Cell Membranes
Current Protein & Peptide Science Baseline Levels of Interleukine-6, Tumor-Necrosis Factor-Alpha and C-Reactive Protein in Treatment Naive Human Immunodeficiency Virus Infected Patients-A Study from a Tertiary-Care Hospital in Eastern India
Current Biomarkers (Discontinued) How Much Gets there and What Does it Do?: The Need for Better Pharmacokinetic and Pharmacodynamic Endpoints in Contemporary Drug Discovery and Development
Current Pharmaceutical Design Inhibitors of ABL and the ABL-T315I Mutation
Current Topics in Medicinal Chemistry Molecular Imaging of Apoptosis with Radio-Labeled Annexin A5 Focused on the Evaluation of Tumor Response to Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Targeting Bcl-2 in CLL
Current Medicinal Chemistry Implications of the Dominant Role of Transporters in Drug Uptake by Cells
Current Topics in Medicinal Chemistry Signal Transduction Therapy with Rationally Designed Kinase Inhibitors
Current Signal Transduction Therapy Caspase-Independent Pathways of Programmed Cell Death: The Unraveling of New Targets of Cancer Therapy?
Current Cancer Drug Targets Signaling Mechanism(S) of Reactive Oxygen Species in Epithelial-Mesenchymal Transition Reminiscent of Cancer Stem Cells in Tumor Progression
Current Stem Cell Research & Therapy Bcl-2-Targeted Antisense Therapy (Oblimersen Sodium): Towards Clinical Reality
Reviews on Recent Clinical Trials Intracellular Calcium, Endothelial Cells and Angiogenesis
Recent Patents on Anti-Cancer Drug Discovery Thioredoxin System Modulation by Plant and Fungal Secondary Metabolites
Current Medicinal Chemistry Antimicrobial Activity of Phenolics and Glucosinolate Hydrolysis Products and their Synergy with Streptomycin against Pathogenic Bacteria
Medicinal Chemistry One Special Question to Start with: Can HIF/NFkB be a Target in Inflammation?
Endocrine, Metabolic & Immune Disorders - Drug Targets